Publications

Selected publications about the compounds are listed below:

Diabetic Nephropathy (SER150)

  • The dual thromboxane receptor antagonist and thromboxane synthase inhibitor EV-077 is a more potent inhibitor of platelet function than aspirin. Fontana P, Alberts P, Sakariassen KS, Bounameaux H, Meyer JP, Santana Sorensen A. J Thromb Haemost. 2011 Oct;9(10):2109-11. http://www.ncbi.nlm.nih.gov/pubmed/21777369
  • EV-077 in vitro inhibits platelet aggregation in type-2 diabetics on aspirin. Sakariassen KS, Femia EA, Daray FM, Podda GM, Razzari C, Pugliano M, Errasti AE, Armesto AR, Nowak W, Alberts P, Meyer JP, Sorensen AS, Cattaneo M, Rothlin RP. Thromb Res. 2012 Nov;130(5):746-52. http://www.ncbi.nlm.nih.gov/pubmed/22959706
  • Single ascending oral dose pharmacokinetics and pharmacodynamics study of EV-077: the specific inhibitor of prostanoid- and isoprostane-induced cellular activation. Richardson A, Sakariassen KS, Meyer JP, Alberts P, Sorensen AS. Eur J Clin Pharmacol. 2013 Mar;69(3):459-65. http://www.ncbi.nlm.nih.gov/pubmed/22815050
  • Effects of the dual TP receptor antagonist and thromboxane synthase inhibitor EV-077 on human endothelial and vascular smooth muscle cells.Petri MH, Tellier C, Michiels C, Ellertsen I, Dogné JM, Bäck M. Biochem Biophys Res Commun. 2013 Nov 15;441(2):393-8. http://www.ncbi.nlm.nih.gov/pubmed/24161392
  • Pharmacodynamic effects of EV-077 in patients with diabetes mellitus and coronary artery disease on aspirin or clopidogrel monotherapy: results of an in vitro pilot investigation. Rollini F, Tello-Montoliu A, Patel R, Darlington A, Wilson RE, Franchi F, Muñiz-Lozano A, Desai B, Bender N, Sakariassen KS, Angiolillo DJ. J Thromb Thrombolysis. 2014;37(2):131-8. http://www.ncbi.nlm.nih.gov/pubmed/23943337
  • Pharmacodynamic effects of EV-077: results of an in vitro pilot investigation in healthy volunteers. Tello-Montoliu A, Rollini F, Desai B, Pasqualino G, Patel R, Sorensen AS, Sakariassen KS, Angiolillo DJ. J Thromb Thrombolysis. 2012 Oct;34(3):297-9. http://www.ncbi.nlm.nih.gov/pubmed/22923024

 Type 2 Diabetes (SER140)

Acute Myocardial Infarction (SER130)

Pulmonary Hypertension (SER100)

Functional pharmacological characterisation of SER100 in cardiovascular health and disease. Villar IC1,2, Bubb KJ1,3, Moyes AJ1, Steiness E4, Gulbrandsen T4, Levy FO5, Hobbs AJhttps://www.ncbi.nlm.nih.gov/pubmed/?term=Functional+pharmacological+characterisation+of+SER100+in+cardiovascular+health+and+disease.

Therapy Resistand Isolated Systolic Hypertension (SER100)